We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,180.50 +13.00 (+0.25%) Dow Futures
38,318.00 +80.00 (+0.21%) Nasdaq Futures
18,229.25 +50.00 (+0.28%) Russell 2000 Futures
2,031.50 +11.70 (+0.58%) Crude Oil
85.38 -0.28 (-0.33%) Gold
2,371.30 -2.80 (-0.12%)
Ultragenyx Pharmaceutical Inc. (RARE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 50.70 |
| Open | 50.15 |
| Bid | 46.93 x 200 |
| Ask | 47.03 x 200 |
| Day's Range | 46.81 - 50.64 |
| 52 Week Range | 31.52 - 54.98 |
| Volume | |
| Avg. Volume | 723,443 |
| Market Cap | 3.87B |
| Beta (5Y Monthly) | 0.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.25 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 89.95 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RARE
Related Research
- Ultragenyx Pharmaceutical Inc.Daily – Vickers Top Buyers & Sellers for 10/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
GlobeNewswireUltragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eas
- GlobeNewswire
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndromeNOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that preclinical and clinical data, including new clinical efficacy and safety data from the expansion cohorts in the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome, will be presented at the 76th Annual American Acad
- GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx E
Insider Monkey10 NASDAQ Stocks with Biggest Upside
In this article, we discuss the 10 NASDAQ stocks with the biggest upside. To skip our detailed analysis, go directly to the 5 NASDAQ Stocks with Biggest Upside. The Nasdaq Composite was the worst performer among the major market indices in 2022 and made a stellar comeback in 2023. The index was down 33% at […]
GuruFocus.comInsider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
Thomas Kassberg, the Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), has sold 11,509 shares of the company on March 11, 2024, according to a recent SEC filing.
GuruFocus.comDirector Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
Director Matthew Fust has sold 12,195 shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on March 7, 2024, according to a recent SEC filing.
Insider Monkey10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Biotech Stocks with Huge Potential. Recent developments, technological as well as optimism related to interest rate reductions, have led to […]
- GlobeNewswire
Ultragenyx to Participate at Investor Conferences in March
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor confere
Simply Wall St.Ultragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) Full Year 2023 Results Key Financial Results Revenue: US$434.2m (up 20% from...
Insider MonkeyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript February 15, 2024 Ultragenyx Pharmaceutical Inc. beats earnings expectations. Reported EPS is $-1.52, expectations were $-1.65. Ultragenyx Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BPMC Blueprint Medicines Corporation | |||
| PTCT PTC Therapeutics, Inc. | |||
| AGIO Agios Pharmaceuticals, Inc. | |||
| QURE uniQure N.V. | |||
| SAGE Sage Therapeutics, Inc. |
Similar to RARE
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BPMC Blueprint Medicines Corporation | |||
| AGIO Agios Pharmaceuticals, Inc. | |||
| MREO Mereo BioPharma Group plc | |||
| IMCR Immunocore Holdings plc | |||
| NUVL Nuvalent, Inc. |
Analyst Price Targets (19)
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 | |
| Maintains | JP Morgan: Overweight to Overweight | 3/18/2024 | |
| Maintains | JP Morgan: Overweight to Overweight | 2/27/2024 | |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 2/27/2024 | |
| Maintains | Canaccord Genuity: Buy to Buy | 2/21/2024 | |
| Maintains | Wedbush: Neutral to Neutral | 2/16/2024 |
Company Profile
60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,276
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
